Article
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
JAMA - 20 Jun 2017
Kuchenbaecker Karoline B, Hopper John L, Barnes Daniel R, Phillips Kelly-Anne, Mooij Thea M, Roos-Blom Marie-José, Jervis Sarah, van Leeuwen Flora E, Milne Roger L, Andrieu Nadine, Goldgar David E, Terry Mary Beth, Rookus Matti A, Easton Douglas F, Antoniou Antonis C, McGuffog Lesley, Evans D Gareth, Barrowdale Daniel, Frost Debra, Adlard Julian, Ong Kai-Ren, Izatt Louise, Tischkowitz Marc, Eeles Ros, Davidson Rosemarie, Hodgson Shirley, Ellis Steve, Nogues Catherine, Lasset Christine, Stoppa-Lyonnet Dominique, Fricker Jean-Pierre, Faivre Laurence, Berthet Pascaline, Hooning Maartje J, van der Kolk Lizet E, Kets Carolien M, Adank Muriel A, John Esther M, Chung Wendy K, Andrulis Irene L, Southey Melissa, Daly Mary B, Buys Saundra S, Osorio Ana, Engel Christoph, Kast Karin, Schmutzler Rita K, Caldes Trinidad, Jakubowska Anna, Simard Jacques, Friedlander Michael L, McLachlan Sue-Anne, Machackova Eva, Foretova Lenka, Tan Yen Y, Singer Christian F, Olah Edith, Gerdes Anne-Marie, Arver Brita, Olsson Håkan
Abstract excerpt
Importance: The clinical management of BRCA1 and BRCA2 mutation carriers requires accurate, prospective cancer risk estimates. Objectives: To estimate age-specific risks of breast, ovarian, and contralateral breast cancer for mutation carriers and to evaluate risk modification by family cancer history and mutation location. Design, Setting, and Participants: Prospective cohort study of 6036 BRCA1 and 3820 BRCA2...
Read the complete abstract on PubMed